
C l a i m s

1. Cell permeable iron chelator for use in the treatment of a solid cancer tumour, wherein the compound is N-(1-pyridine-2-yl-methylidene)-N-(*9H*-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine or a pharmaceutically acceptable salt or complex thereof of the general formula I, wherein R is H or methyl, R^1 is H or C_1-C_4 alkyl, R^2 is H or C_1-C_4 alkyl.



I

2. The cell permeable iron chelator for use according to claim 1, wherein R is methyl.

3. The cell permeable iron chelator for use according to claim 1, wherein both of R, R^1 are methyl.

4. The cell permeable iron chelator for use according to claim 1 or 2, wherein R^1 is methyl, in particular 6-methyl or 8-methyl.

5. The cell permeable iron chelator for use according to claim 1, wherein R is methyl, R^1 is 8-methyl, and R^2 is H.


6. The cell permeable iron chelator for use according to claim 1, wherein

R is	R^1 is	R^2 is	
methyl	8-methyl	H;	or
methyl	H	H;	or
methyl	6-methyl	H;	or
H	6-methyl	H;	or,
H	8-methyl	CH_3.	

7. Pharmaceutical composition for use in the treatment of a solid cancer tumour comprising or consisting of the cell permeable iron chelator of any of claims 1 to 6 and a pharmaceutically suitable carrier.

8. Pharmaceutical composition for use according to claim 7, comprising a cancer combating effective dose of said compound.

9. Use of a cell permeable iron chelator in the manufacture of a medicament for the treatment of a solid cancer tumour, wherein the compound is N-(1-pyridine-2-yl-methylidene)-N-(*9H*-1,3,4,9-tetraaza-fluoren-2-yl)-hydrazine or a pharmaceutically acceptable salt or complex thereof of the general formula I, wherein R is H or methyl, R^1 is H or C_1-C_4 alkyl, R^2 is H or C_1-C_4 alkyl.



I

10. The use according to claim 9, wherein R is methyl.

11. The use according to claim 9, wherein both of R, R^1 are methyl.

12. The use according to claim 9 or 10, wherein R^1 is methyl, in particular 6-methyl or 8-methyl.

13. The use according to claim 9, wherein R is methyl, R^1 is 8-methyl, and R^2 is H.

14. The use according to claim 9, wherein

R is	R^1 is	R^2 is	
methyl	8-methyl	H;	or
methyl	H	H;	or
methyl	6-methyl	H;	or

H	6-methyl	H;	or,
H	8-methyl	CH_3.	

15. Use of a pharmaceutical composition comprising or consisting of the cell permeable iron chelator of any of claims 1 to 6 and a pharmaceutically suitable carrier in the manufacture of a medicament for the treatment of a solid cancer tumour.

16. The use according to claim 15, comprising a cancer combating effective dose of said compound.